In Reply To: Comment on: Improved local control following dose-escalated stereotactic ablative radiation therapy (SABR) for metastatic sarcomas: An international multi-institutional experience
Author:
- 18 December 2023
- journal article
- letter
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 192, 110058
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- The HILUS-Trial—a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body RadiotherapyJournal of Thoracic Oncology, 2021
- Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non–Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 TrialJournal of Clinical Oncology, 2019
- Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG)International Journal of Cancer, 2018
- Pulmonary Metastases From Soft Tissue SarcomaAnnals of Surgery, 1999